165 related articles for article (PubMed ID: 10481530)
21. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
[TBL] [Abstract][Full Text] [Related]
22. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of serum anti-p53 antibody measurement for colorectal cancer].
Kuwabara K; Kumamoto K; Ishibashi K; Ohsawa T; Kumagai Y; Baba H; Tsuji Y; Haga N; Ishida H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2167-9. PubMed ID: 23268012
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Iwasaki K; Makino H; Natsume T; Kouno T; Kondo S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):879-83. PubMed ID: 10897215
[TBL] [Abstract][Full Text] [Related]
25. Relationship between degree of cellular differentiation in colorectal cancer and topographical distribution.
Linares Santiago E; Sánchez Calzado JA; Capitán Morales L; Gómez Parra M; González Mariscal MJ; Mendoza Olivares FJ; Sáenz Dana M; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2002 Feb; 94(2):78-87. PubMed ID: 12185656
[TBL] [Abstract][Full Text] [Related]
26. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
27. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
28. The relationship between circulating interleukin-6 and carcinoembryonic antigen in patients with colorectal cancer.
Nakagoe T; Tsuji T; Sawai T; Tanaka K; Hidaka S; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Sugawara K; Inokuchi N; Kamihira S
Anticancer Res; 2003; 23(4):3561-4. PubMed ID: 12926107
[TBL] [Abstract][Full Text] [Related]
29. Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.
Szajda SD; Snarska J; Jankowska A; Roszkowska-Jakimiec W; Puchalski Z; Zwierz K
Hepatogastroenterology; 2008; 55(82-83):388-93. PubMed ID: 18613372
[TBL] [Abstract][Full Text] [Related]
30. Quantitative estimation of CEA and CK20 expression in tumour tissue of colorectal cancer and its liver metastases with reverse transcription and real-time PCR.
Cerna M; Holubec L; Pesta M; Kormunda S; Topolcan O; Cerny R
Anticancer Res; 2006; 26(1B):803-8. PubMed ID: 16739357
[TBL] [Abstract][Full Text] [Related]
31. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
32. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
33. Combination of serum carcino-embryonic antigen and C-reactive protein--a useful test in preoperative staging of colorectal cancer.
Stamatiadis AP; Manouras AJ; Triantos GN; Katergiannakis VA; Apostolidis NS
Eur J Surg Oncol; 1992 Feb; 18(1):41-3. PubMed ID: 1737592
[TBL] [Abstract][Full Text] [Related]
34. The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
Bergström S; Dreilich M; Wagenius G; Brattström D; Larsson A; Hesselius P; Bergqvist M
In Vivo; 2004; 18(5):615-20. PubMed ID: 15523902
[TBL] [Abstract][Full Text] [Related]
35. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Boonsong A; Curran S; McKay JA; Cassidy J; Murray GI; McLeod HL
Hum Pathol; 2002 Nov; 33(11):1114-9. PubMed ID: 12454816
[TBL] [Abstract][Full Text] [Related]
37. Metastatic potential in T1 and T2 colorectal cancer.
Fang WL; Chang SC; Lin JK; Wang HS; Yang SH; Jiang JK; Chen WC; Lin TC
Hepatogastroenterology; 2005; 52(66):1688-91. PubMed ID: 16334758
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
39. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
[TBL] [Abstract][Full Text] [Related]
40. [Correlation between serum p53 antibody and chemosensitivity in patient with esophageal cancer].
Wang MH; Li YP; Wang XD; Zhang H; Xiong LH; Huang HZ
Ai Zheng; 2004 Apr; 23(4):467-70. PubMed ID: 15087041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
